FK614, a Novel Peroxisome Proliferator-Activated Receptor γ Modulator, Induces Differential Transactivation Through a Unique Ligand-Specific Interaction With Transcriptional Coactivators
スポンサーリンク
概要
- 論文の詳細を見る
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-dependent transcriptional factor implicated in regulating adipogenesis, glucose homeostasis, and in mediating the action of the insulin sensitizing anti-diabetic thiazolidinedione (TZD) compounds. [3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3-H-benzimidazole-5-carboxamide] (FK614) is a structurally novel PPARγ agonist that demonstrates potent anti-diabetic activity in vivo. Herein, we describe that FK614 is a selective PPARγ ligand with specific transactivation properties that are dependent upon the context of coactivators. FK614 dissociates the corepressors NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptors) from PPARγ as effectively as rosiglitazone and pioglitazone, but can also differentially induce a ligand specific interaction of PPARγ with coactivators. The amount of CBP (CREB-binding protein) and SRC-1 (steroid receptor coactivator-1) recruited by FK614 was less than that induced by rosiglitazone and pioglitazone, but FK614 caused similar PGC-1α (PPARγ coactivator-1α) recruitment as these compounds. As a consequence of these ligand-specific differences in the strength of ligand-type specific interactions of PPARγ and coactivators, FK614 functions as a partial or full agonist for transcriptional activation depending upon the amount of specific coactivators in cells following overexpression. In conclusion, FK614 is a novel, non-TZD type, and selective PPARγ modulator whose pharmacological properties are distinct from rosiglitazone and pioglitazone.
- 社団法人 日本薬理学会の論文
- 2005-12-20
著者
-
FUJIMURA TAKAO
Pharmacological Research Laboratories, Fujisawa Pharmaceutical Co. Ltd.
-
FUJIMURA Takao
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
ARAMORI Ichiro
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
MUTOH Seitaro
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
Mutoh Seitaro
Pharmacology Res. Labs Astellas Pharma Inc. Jpn
-
Aramori Ichiro
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Fujimura Takao
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Fujimura Takao
Pharmacological Research Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
SAKUMA Hiroyuki
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
KONISHI Satoko
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
OE Tomoya
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
HOSOGAI Naomi
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
KIMURA Chiaki
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
Oe Tomoya
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Hosogai Naomi
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Kimura Chiaki
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Konishi Satoko
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Sakuma Hiroyuki
Pharmacology Research Laboratories Astellas Pharma Inc.
関連論文
- An Approach to High-Level Production of Cephalosporin Acylase from Pseudomonas strain N176 in Escherichia coli
- Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia(Molecular and Cell Biology)
- Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat(Pharmacology)
- Evaluation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtype Selectivity of a Variety of Anti-inflammatory Drugs Based on a Novel Assay for PPARδ(β)
- Unique Properties of Coactivator Recruitment Caused by Differential Binding of FK614, an Anti-diabetic Agent, to Peroxisome Proliferator-Activated Receptor γ(Molecular and Cell Biology)
- FK614, a Novel Peroxisome Proliferator-Activated Receptor γ Modulator, Induces Differential Transactivation Through a Unique Ligand-Specific Interaction With Transcriptional Coactivators
- Efficacy of Oral Treatment With Tacrolimus in the Renal Transplant Model in Cynomolgus Monkeys
- Effect of a New Immunosuppressant Histon Deacetylase (HDAC) Inhibitor FR276457 in a Rat Cardiac Transplant Model(Pharmacology)
- Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations
- Determination of Antifungal Activities in Serum Samples from Mice Treated with Different Antifungal Drugs Allows Detection of an Active Metabolite of Itraconazole
- Chemical Modification and Site-Directed Mutagenesis of Tyrosine Residues in Cephalosporin C Acylase from Pseudomonas Strain N176
- A Novel 7-β-(4-Carboxybutanamido)-Cephalosporanic Acid Acylase Isolated from Pseudomonas Strain C427 and Its High-Level Production in Escherichia coli
- Large Scale Purification of Recombinant Insulin-Like Growth Factor I (IGF-I, Mecasermin) from a Fused Protein Produced in Escherichia coli
- Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds
- Pharmacological Properties of FK886, a New, Centrally Active Neurokinin-1 Receptor Antagonist